Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis

Immunopharmacology and Immunotoxicology

Volumn 34, Issue 4, 2012, Pages 548-560

  Girolomoni, Giampiero ^a   Altomare, Gianfranco ^b,c   Ayala, Fabio ^d   Berardesca, Enzo ^e   Calzavara Pinton, Piergiacomo ^f   Chimenti, Sergio ^g   Peserico, Andrea ^h   Puglisi Guerra, Antonio ⁱ   Vena, Gino Antonio ^j  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^f Spedali Civili of Brescia ^*  (Italy)

^g UNIVERSITY OF ROME TOR VERGATA   (Italy)

^h UNIVERSITY OF PADOVA   (Italy)

ⁱ Messina Hospital   (Italy)

^j UNIVERSITY OF BARI   (Italy)

more..

Author keywords

Adalimumab; Biological drugs; Etanercept; Golimumab; Infliximab; Psoriasis; Psoriatic arthritis; Registry; safety

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTINUCLEAR ANTIBODY; CERTOLIZUMAB PEGOL; CORTICOSTEROID; ETANERCEPT; GAMMA INTERFERON; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 23; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; USTEKINUMAB; VIRUS RNA;

ANTIBODY TITER; AUTOIMMUNITY; CANCER RISK; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CELL DIFFERENTIATION; DRUG CONTRAINDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCARDITIS; ENDOPHTHALMITIS; EUROPE; HEARING LOSS; HEPATITIS C; HISTOPLASMOSIS; HUMAN; IMMUNOSURVEILLANCE; INCIDENCE; INFECTION RISK; INFLAMMATION; INJECTION SITE REACTION; LATENT TUBERCULOSIS; LEGIONNAIRE DISEASE; LEUKOCYTE MIGRATION; LISTERIACEAE; LIVER INJURY; LIVER TOXICITY; LONG TERM CARE; LOWER RESPIRATORY TRACT INFECTION; LYMPHOMA; MEDLINE; NOCARDIOSIS; OPTIC NERVE DISEASE; OSTEOCLAST; OSTEOMYELITIS; PHOTOSENSITIVITY; PREGNANCY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RASH; REGISTER; REVIEW; SIDE EFFECT; SKIN DEFECT; SKIN INJURY; SOLID TUMOR; SPONDYLOARTHROPATHY; THROMBOCYTE COUNT; TUBERCULOSIS; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFECTION; LYMPHOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863788258     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2011.653646     Document Type: Review

References (177)

1. Menter, A., Gottlieb, A., Feldman, S.R., Van Voorhees, A.S., Leonardi, C.L., Gordon, K.B., Lebwohl, M., Koo, J.Y., Elmets, C.A., Korman, N.J., Beutner, K.R., Bhushan, R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008, 58, 826-850.
2. Gottlieb, A., Korman, N.J., Gordon, K.B., Feldman, S.R., Lebwohl, M., Koo, J.Y., Van Voorhees, A.S., Elmets, C.A., Leonardi, C.L., Beutner, K.R., Bhushan, R., Menter, A. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008, 58, 851-864.
3. Davidovici, B.B., Sattar, N., Prinz, J.C., Jörg, P.C., Puig, L., Emery, P., Barker, J.N., van de Kerkhof, P., Stǎhle, M., Nestle, F.O., Girolomoni, G., Krueger, J.G. Psoriasis and systemic inflammatory diseases: Potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010, 130, 1785-1796.
4. Gisondi, P., Girolomoni, G. Psoriasis and atherothrombotic diseases: Disease-specific and non-disease-specific risk factors. Semin Thromb Hemost 2009, 35, 313-324.
5. Finlay, A.Y. Current severe psoriasis and the rule of tens. Br J Dermatol 2005, 152, 861-867.
6. Therapeutic Goods Administration-Australian Government's Department of Health and Ageing. Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis [online]. [cited 2010 December 15]; Available from: Http://www.tga.gov.au/docs/pdf/euguide/ewp/245402en.pdf.
7. Gisondi, P., Girolomoni, G. Biologic therapies in psoriasis: A new therapeutic approach. Autoimmun Rev 2007, 6, 515-519.
8. Castelo-Soccio, L., Van Voorhees, A.S. Long-term efficacy of biologics in dermatology. Dermatol Ther 2009, 22, 22-33.
9. Gladman, D.D. Psoriatic arthritis. Dermatol Ther 2009, 22, 40-55.
10. Weger, W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol 2010, 160, 810-820.
11. Fantuzzi, F., Del Giglio, M., Gisondi, P., Girolomoni, G. Targeting tumor necrosis factor a in psoriasis and psoriatic arthritis. Expert Opin Ther Targets 2008, 12, 1085-1096.
12. Miller, D.W., Feldman, S.R. Cost-effectiveness of moderate-tosevere psoriasis treatment. Expert Opin Pharmacother 2006, 7, 157-167.
13. Chaudhari, U., Romano, P., Mulcahy, L.D., Dooley, L.T., Baker, D.G., Gottlieb, A.B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet 2001, 357, 1842-1847.
14. Langley, R.G., Strober, B.E., Gu, Y., Rozzo, S.J., Okun, M.M. Benefitrisk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. Br J Dermatol 2010, 162, 1349-1358.
15. Ravindran, V., Scott, D.L., Choy, E.H. A systematic review and meta-analysis of efficacy and toxicity of disease modifying antirheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 2008, 67, 855-859.
16. Kircik, L.H., Del Rosso, J.Q. Anti-TNF agents for the treatment of psoriasis. J Drugs Dermatol 2009, 8, 546-559.
17. Korkina, L., Trakhtman, P., De Luca, C., Leoni, L., Raskovic, D., Pastore, S. Efficacy and safety of biologicals against immunemediated diseases: Do benefits outweigh risks? Drugs Today 2010, 46, 119-136.
18. Sfikakis, P.P. The first decade of biologic TNF antagonists in clinical practice: Lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010, 11, 180-210.
19. Rawlins, M. De testimonio: On the evidence for decisions about the use of therapeutic interventions. Lancet 2008, 372, 2152-2161.
20. Silverman, S.L. From randomized controlled trials to observational studies. Am J Med 2009, 122, 114-120.
21. Albrecht, J., Werth, V.P., Bigby, M. The role of case reports in evidence-based practice, with suggestions for improving their reporting. J Am Acad Dermatol 2009, 60, 412-418.
22. Gomez-Reino, J.J., Carmona, L.; BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period. Arthritis Res Ther 2006, 8, R29.
23. Saad, A.A., Ashcroft, D.M., Watson, K.D., Hyrich, K.L., Noyce, P.R., Symmons, D.P.; British Society for Rheumatology Biologics Register. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: Observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 2009, 11, R52.
24. Glintborg, B., Østergaard, M., Dreyer, L., Krogh, N.S., Tarp, U., Hansen, M.S., Rifbjerg-Madsen, S., Lorenzen, T., Hetland, M.L. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor a therapy: Results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011, 63, 382-390.
25. Salliot, C., Gossec, L., Ruyssen-Witrand, A., Luc, M., Duclos, M., Guignard, S., Dougados, M. Infections during tumour necrosis factor- a blocker therapy for rheumatic diseases in daily practice: A systematic retrospective study of 709 patients. Rheumatology (Oxford) 2007, 46, 327-334.
26. Askling, J., Dixon, W. The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008, 20, 138-144.
27. Dixon, W.G., Watson, K., Lunt, M., Hyrich, K.L., Silman, A.J., Symmons, D.P.; British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006, 54, 2368-2376.
28. Dixon W, Hyrich KL, Watson K, Lunt M. The influence of anti- TNF therapy upon the incidence and severity of serious lower respirtory tract infections in patients with rheumatoid arthritis: Results from the BSR biologics register (BSRBR) [abstract no. 157]. Rheumatology (Oxford) 2008;47:ii47.
29. Carmona, L., Gómez-Reino, J.J.; BIOBADASER Group. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006, 8, R72.
30. Grijalva, C.G., Chen, L., Delzell, E., Baddley, J.W., Beukelman, T., Winthrop, K.L., Griffin, M.R., Herrinton, L.J., Liu, L., Ouellet- Hellstrom, R., Patkar, N.M., Solomon, D.H., Lewis, J.D., Xie, F., Saag, K.G., Curtis, J.R. Initiation of tumor necrosis factor- A antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011, 306, 2331-2339.
31. Lee, J.H., Slifman, N.R., Gershon, S.K., Edwards, E.T., Schwieterman, W.D., Siegel, J.N., Wise, R.P., Brown, S.L., Udall, J.N. Jr, Braun, M.M. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor a antagonists infliximab and etanercept. Arthritis Rheum 2002, 46, 2565-2570.
32. Slifman, N.R., Gershon, S.K., Lee, J.H., Edwards, E.T., Braun, M.M. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor a-neutralizing agents. Arthritis Rheum 2003, 48, 319-324.
33. Wallis, R.S., Broder, M., Wong, J., Lee, A., Hoq, L. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 2005, 41 Suppl 3, S194-S198.
34. Salmon-Ceron, D., Tubach, F., Lortholary, O., Chosidow, O., Bretagne, S., Nicolas, N., Cuillerier, E., Fautrel, B., Michelet, C., Morel, J., Puéchal, X., Wendling, D., Lemann, M., Ravaud, P., Mariette, X.; RATIO group. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011, 70, 616-623.
35. Al-Tawfiq, J.A., Al-Khatti, A.A. Disseminated systemic Nocardia farcinica infection complicating alefacept and infliximab therapy in a patient with severe psoriasis. Int J Infect Dis 2010, 14, e153-e157.
36. Eisendle, K., Fritsch, P. Fatal fulminant legionnaires' disease in a patient with severe erythodermic psoriasis treated with infliximab after long-term steroid therapy. Br J Dermatol 2005, 152, 585-586.
37. Kamili, Q.A., Menter, A. Atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy. J Drugs Dermatol 2010, 9, 57-60.
38. Kelesidis, T., Salhotra, A., Fleisher, J., Uslan, D.Z. Listeria endocarditis in a patient with psoriatic arthritis on infliximab: Are biologic agents as treatment for inflammatory arthritis increasing the incidence of Listeria infections? J Infect 2010, 60, 386-396.
39. Sri, J.C., Tsai, C.L., Deng, A., Gaspari, A.A. Osteomyelitis occurring during infliximab treatment of severe psoriasis. J Drugs Dermatol 2007, 6, 207-210.
40. Stewart, M.W., Alvarez, S., Ginsburg, W.W., Shetty, R., McLain, W.C., Sleater, J.P. Visual recovery following Mycobacterium chelonae endophthalmitis. Ocul Immunol Inflamm 2006, 14, 181-183.
41. Dixon, W.G., Hyrich, K.L., Watson, K.D., Lunt, M., Galloway, J., Ustianowski, A., Symmons, D.P.; B S R B R Control Centre Consortium; BSR Biologics Register. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti- TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010, 69, 522-528.
42. Harris, J., Keane, J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol 2010, 161, 1-9.
43. Mohan, V.P., Scanga, C.A., Yu, K., Scott, H.M., Tanaka, K.E., Tsang, E., Tsai, M.M., Flynn, J.L., Chan, J. Effects of tumor necrosis factor a on host immune response in chronic persistent tuberculosis: Possible role for limiting pathology. Infect Immun 2001, 69, 1847-1855.
44. Wallis, R.S., Broder, M.S., Wong, J.Y., Hanson, M.E., Beenhouwer, D.O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004, 38, 1261-1265.
45. Askling, J., Fored, C.M., Brandt, L., Baecklund, E., Bertilsson, L., Cöster, L., Geborek, P., Jacobsson, L.T., Lindblad, S., Lysholm, J., Rantapää-Dahlqvist, S., Saxne, T., Romanus, V., Klareskog, L., Feltelius, N. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005, 52, 1986-1992.
46. Huo, R., Romanelli, P. Etanercept therapy for psoriasis in a patient with active pulmonary tuberculosis. Am J Clin Dermatol 2010, 11 Suppl 1, 39-40.
47. Tubach, F., Salmon, D., Ravaud, P., Allanore, Y., Goupille, P., Bréban, M., Pallot-Prades, B., Pouplin, S., Sacchi, A., Chichemanian, R.M., Bretagne, S., Emilie, D., Lemann, M., Lortholary, O., Lorthololary, O., Mariette, X.; Research Axed on Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009, 60, 1884-1894.
48. Bruns, H., Meinken, C., Schauenberg, P., Härter, G., Kern, P., Modlin, R.L., Antoni, C., Stenger, S. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 2009, 119, 1167-1177.
49. Mariette, X. Lymphoma, rheumatoid arthritis, and TNF a antagonists. Joint Bone Spine 2010, 77, 195-197.
50. Haider, A.S., Cardinale, I.R., Whynot, J.A., Krueger, J.G. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes. J Investig Dermatol Symp Proc 2007, 12, 9-15.
51. Wallis, R.S. Reactivation of latent tuberculosis by TNF blockade: The role of interferon gamma. J Investig Dermatol Symp Proc 2007, 12, 16-21.
52. Saad, A.A., Ashcroft, D.M., Watson, K.D., Symmons, D.P., Noyce, P.R., Hyrich, K.L.; BSRBR. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: An observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010, 49, 697-705.
53. Centers for Disease Control and Prevention. Guide for primary health care providers: Targeted tuberculin testing and treatment of latent tuberculosis infection [online]. 2008 [cited 2010 September 3]; Available from: Www.cdc.gov/tb/pubs/LTBI/ pdf/TargetedLTBI05.pdf.
54. Koike, R., Takeuchi, T., Eguchi, K., Miyasaka, N.; Japan College of Rheumatology. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 2007, 17, 451-458.
55. Perlmutter, A., Mittal, A., Menter, A. Tuberculosis and tumour necrosis factor- a inhibitor therapy: A report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. Br J Dermatol 2009, 160, 8-15.
56. Nelson, D.R., Lim, H.L., Marousis, C.G., Fang, J.W., Davis, G.L., Shen, L., Urdea, M.S., Kolberg, J.A., Lau, J.Y. Activation of tumor necrosis factor- a system in chronic hepatitis C virus infection. Dig Dis Sci 1997, 42, 2487-2494.
57. Peterson, J.R., Hsu, F.C., Simkin, P.A., Wener, M.H. Effect of tumour necrosis factor a antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003, 62, 1078-1082.
58. Zein, N.N.; Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: A phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005, 42, 315-322.
59. Frankel, A.J., Van Voorhees, A.S., Hsu, S., Korman, N.J., Lebwohl, M.G., Bebo, B.F. Jr, Gottlieb, A.B.; National Psoriasis Foundation. Treatment of psoriasis in patients with hepatitis C: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009, 61, 1044-1055.
60. De Simone, C., Paradisi, A., Capizzi, R., Carbone, A., Siciliano, M., Amerio, P.L. Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol 2006, 54, 1102-1104.
61. Gandhi, R.K., Pickup, T., Sheth, P.B. Is etanercept safe for treating plaque psoriasis in a patient with chronic hepatitis C virus infection? Arch Dermatol 2010, 146, 1151-1152.
62. Benucci, M., Manfredi, M., Mecocci, L. Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B. J Clin Rheumatol 2008, 14, 245-246.
63. Cansu, D.U., Kalifoglu, T., Korkmaz, C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 2008, 35, 421-424.
64. Montiel, P.M., Solis, J.A., Chirinos, J.A.,Casis, B., Sánchez, F., Rodríguez, S. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008, 28, 718-720.
65. Sakellariou, G.T., Chatzigiannis, I. Long-term anti-TNF a therapy for ankylosing spondylitis in two patients with chronic HBV infection. Clin Rheumatol 2007, 26, 950-952.
66. Fotiadou, C., Lazaridou, E., Ioannides, D. Safety of anti-tumour necrosis factor- A agents in psoriasis patients who were chronic hepatitis B carriers: A retrospective report of seven patients and brief review of the literature. J Eur Acad Dermatol Venereol 2011, 25, 471-474.
67. Strangfeld, A., Listing, J., Herzer, P., Liebhaber, A., Rockwitz, K., Richter, C., Zink, A. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF- A agents. JAMA 2009, 301, 737-744.
68. Perez-Zafrilla B, Garcia Doval I, Carmona L. Rates of herpes zoster in patients with rheumatoid arthritis and treatment with TNF antagonists. Incidence rate in BIOBADASER cohort in comparison with EMECAR cohort [abstract no. FRI0129]. Ann Rheum Dis 2008;67:327.
69. Kling, M.C., Larian, A.A., Scordi-Bello, I., Emer, J., Lebwohl, M.G. Fatal influenza A (H1N1) respiratory tract infection in a patient having psoriasis treated with infliximab. Arch Dermatol 2010, 146, 651-654.
70. Petersen, B., Lorentzen, H. Cytomegalovirus complicating biological immunosuppressive therapy in two patients with psoriasis receiving treatment with etanercept or efalizumab. Acta Derm Venereol 2008, 88, 523-524.
71. Messina, M., Scichilone, N., Guddo, F., Bellia, V. Rapidly progressive organising pneumonia associated with cytomegalovirus infection in a patient with psoriasis. Monaldi Arch Chest Dis 2007, 67, 165-168.
72. Berger, J.R. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf 2010, 33, 969-983.
73. Menon, K., Van Voorhees, A.S., Bebo, B.F. , Gladman, D.D., Hsu, S., Kalb, R.E., Lebwohl, M.G., Strober, B.E.; National Psoriasis Foundation. Psoriasis in patients with HIV infection: From the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2010, 62, 291-299.
74. Cepeda, E.J., Williams, F.M., Ishimori, M.L., Weisman, M.H., Reveille, J.D. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008, 67, 710-712.
75. Linardaki, G., Katsarou, O., Ioannidou, P., Karafoulidou, A., Boki, K. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol 2007, 34, 1353-1355.
76. Mikhail, M., Weinberg, J.M., Smith, B.L. Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus. Arch Dermatol 2008, 144, 453-456.
77. Tsiodras, S., Samonis, G., Boumpas, D.T., Kontoyiannis, D.P. Fungal infections complicating tumor necrosis factor a blockade therapy. Mayo Clin Proc 2008, 83, 181-194.
78. Adams, A.E., Zwicker, J., Curiel, C., Kadin, M.E., Falchuk, K.R., Drews, R., Kupper, T.S. Aggressive cutaneous T-cell lymphomas after TNF a blockade. J Am Acad Dermatol 2004, 51, 660-662.
79. Berthelot, C., Cather, J., Jones, D., Duvic, M. Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy. Clin Lymphoma Myeloma 2006, 6, 329-332.
80. Brown, S.L., Greene, M.H., Gershon, S.K., Edwards, E.T., Braun, M.M. Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002, 46, 3151-3158.
81. Mahé, E., Descamps, V., Grossin, M., Fraitag, S., Crickx, B. CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol 2003, 149, 170-173.
82. Bongartz, T., Sutton, A.J., Sweeting, M.J., Buchan, I., Matteson, E.L., Montori, V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295, 2275-2285.
83. Dziadzio, M., Smith, R. Meta-analysis is no substitute for a comprehensive national registry. Clin Rheumatol 2007, 26, 1134-1135.
84. Askling, J., Baecklund, E., Granath, F., Geborek, P., Fored, M., Backlin, C., Bertilsson, L., Cöster, L., Jacobsson, L.T., Lindblad, S., Lysholm, J., Rantapää-Dahlqvist, S., Saxne, T., van Vollenhoven, R., Klareskog, L., Feltelius, N. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: Relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009, 68, 648-653.
85. Wolfe, F., Michaud, K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study. Arthritis Rheum 2007, 56, 2886-2895.
86. Watson K., Dixon W., Hyrich K.L., Lunt M. Influence of anti-TNF therapy and previous malignancy on cancer incidence in patients with rheumatoid arthritis (RA): Results from the BSR Biologics Register (BSRBR) [abstract no. OP25]. Rheumatology (Oxford) 2006;45:i10.
87. Comte, C., Guilhou, J.J., Guillot, B., Dereure, O. Rapid onset and fatal outcome of two squamous cell carcinomas of the genitalia in a patient treated with etanercept for cutaneous psoriasis. Dermatology (Basel) 2008, 217, 284-285.
88. Gelfand, J.M., Berlin, J., Van Voorhees, A., Margolis, D.J. Lymphoma rates are low but increased in patients with psoriasis: Results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003, 139, 1425-1429.
89. Gelfand, J.M., Shin, D.B., Neimann, A.L., Wang, X., Margolis, D.J., Troxel, A.B. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006, 126, 2194-2201.
90. Ganguly, S. Leukemic phase of follicular lymphoma after treatment with etanercept in a patient with psoriasis. Am J Clin Dermatol 2009, 10, 125-126.
91. Chong, B.F., Wong, H.K. Treatment of psoriasis with etanercept in a patient with a history of primary B-cell lymphoma. Clin Exp Dermatol 2009, 34, e11-e13.
92. Mariette, X., Tubach, F., Bagheri, H., Bardet, M., Berthelot, J.M., Gaudin, P., Heresbach, D., Martin, A., Schaeverbeke, T., Salmon, D., Lemann, M., Hermine, O., Raphael, M., Ravaud, P. Lymphoma in patients treated with anti-TNF: Results of the 3-year prospective French RATIO registry. Ann Rheum Dis 2010, 69, 400-408.
93. Karampetsou, M.P., Liossis, S.N., Sfikakis, P.P. TNF- A antagonists beyond approved indications: Stories of success and prospects for the future. QJM 2010, 103, 917-928.
94. Atzeni, F., Turiel, M., Caporali, R., Cavagna, L., Tomasoni, L., Sitia, S., Sarzi-Puttini, P. The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. Autoimmun Rev 2010, 9, 835-839.
95. Ryan, C., Leonardi, C.L., Krueger, J.G., Kimball, A.B., Strober, B.E., Gordon, K.B., Langley, R.G., de Lemos, J.A., Daoud, Y., Blankenship, D., Kazi, S., Kaplan, D.H., Friedewald, V.E., Menter, A. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: A meta-analysis of randomized controlled trials. JAMA 2011, 306, 864-871.
96. Tristano, A.G. Neurological adverse events associated with antitumor necrosis factor a treatment. J Neurol 2010, 257, 1421-1431.
97. Lozeron, P., Denier, C., Lacroix, C., Adams, D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-a-blocker therapy. Arch Neurol 2009, 66, 490-497.
98. Mohan, N., Edwards, E.T., Cupps, T.R., Oliverio, P.J., Sandberg, G., Crayton, H., Richert, J.R., Siegel, J.N. Demyelination occurring during anti-tumor necrosis factor a therapy for inflammatory arthritides. Arthritis Rheum 2001, 44, 2862-2869.
99. Robinson, W.H., Genovese, M.C., Moreland, L.W. Demyelinating and neurologic events reported in association with tumor necrosis factor a antagonism: by what mechanisms could tumor necrosis factor a antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001, 44, 1977-1983.
100. Sicotte, N.L., Voskuhl, R.R. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001, 57, 1885-1888.
101. Winkelmann, A., Patejdl, R., Wagner, S., Benecke, R., Zettl, U.K. Cerebral MRI lesions and anti-tumor necrosis factor- a therapy. J Neurol 2008, 255 Suppl 6, 109-114.
102. Chan, J.W., Castellanos, A. Infliximab and anterior optic neuropathy: Case report and review of the literature. Graefes Arch Clin Exp Ophthalmol 2010, 248, 283-287.
103. Chung, J.H., Van Stavern, G.P., Frohman, L.P., Turbin, R.E. Adalimumab-associated optic neuritis. J Neurol Sci 2006, 244, 133-136.
104. Giani, T., Simonini, G., Lunardi, C., Puccetti, A., De Martino, M., Falcini, F. Juvenile psoriatic arthritis and acquired sensorineural hearing loss in a teenager: Is there an association? Clin Exp Rheumatol 2006, 24, 344-346.
105. Alexopoulou, A., Koskinas, J., Soultati, A., Katsaounis, P., Kilidireas, K., Papageorgiou, C., Antoniou, C., Katsambas, A., Archimandritis, A. Acute bilateral phrenic neuropathy following treatment with adalimumab. Clin Rheumatol 2009, 28, 1337-1340.
106. Argyriou, A.A., Makridou, A., Karanasios, P., Makris, N. Axonal common peroneal nerve palsy and delayed proximal motor radial conduction block following infliximab treatment. J Pain Symptom Manage 2009, 38, e3-e5.
107. Hanaoka, B.Y., Libecco, J., Rensel, M., Hajj-Ali, R.A. Peripheral mononeuropathy with etanercept use: Case report. J Rheumatol 2008, 35, 182.
108. Vedove, C.D., Del Giglio, M., Schena, D., Girolomoni, G. Druginduced lupus erythematosus. Arch Dermatol Res 2009, 301, 99-105.
109. Pink, A.E., Fonia, A., Allen, M.H., Smith, C.H., Barker, J.N. Antinuclear antibodies associate with loss of response to antitumour necrosis factor- a therapy in psoriasis: A retrospective, observational study. Br J Dermatol 2010, 162, 780-785.
110. Abunasser, J., Forouhar, F.A., Metersky, M.L. Etanercept-induced lupus erythematosus presenting as a unilateral pleural effusion. Chest 2008, 134, 850-853.
111. De Bandt, M., Sibilia, J., LeLo't, X., Prouzeau, S., Fautrel, B., Marcelli, C., Boucquillard, E., Siame, J.L., Mariette, X.; Club Rhumatismes et Inflammation. Systemic lupus erythematosus induced by anti-tumour necrosis factor a therapy: A French national survey. Arthritis Res Ther 2005, 7, R545-R551.
112. Exarchou, S.A., Voulgari, P.V., Markatseli, T.E., Zioga, A., Drosos, A.A. aImmune-mediated skin lesions in patients treated with anti-tumour necrosis factor inhibitors. Scand J Rheumatol 2009, 38, 328-331.
113. Farah, R.E., Shay, M.D. Pulmonary sarcoidosis associated with etanercept therapy. Pharmacotherapy 2007, 27, 1446-1448.
114. Izzi, S., Francesconi, F., Visca, P., Altieri, A., De Mutiis, C., Trevisan, G., Bonifati, C. Pulmonary sarcoidosis in a patient with psoriatic arthritis during infliximab therapy. Dermatol Online J 2010, 16, 16.
115. Klein, R., Rosenbach, M., Kim, E.J., Kim, B., Werth, V.P., Dunham, J. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 2010, 146, 780-784.
116. Ramos-Casals, M., Brito-Zerón, P., Muñoz, S., Soria, N., Galiana, D., Bertolaccini, L., Cuadrado, M.J., Khamashta, M.A. Autoimmune diseases induced by TNF-targeted therapies: Analysis of 233 cases. Medicine (Baltimore) 2007, 86, 242-251.
117. Collamer, A.N., Battafarano, D.F. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: Clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010, 40, 233-240.
118. Ko, J.M., Gottlieb, A.B., Kerbleski, J.F. Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases. J Dermatolog Treat 2009, 20, 100-108.
119. Reich, K., Nestle, F.O., Papp, K., Ortonne, J.P., Evans, R., Guzzo, C., Li, S., Dooley, L.T., Griffiths, C.E.; EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet 2005, 366, 1367-1374.
120. US Food and Drug Administration. Warning on hepatotoxicity with infliximab [online]. 2002 [cited 2010 September 4]; Available from: Http://www.fda.gov/medwatch/SAFETY/2004/remicade- DHCP-dec04.pdf.
121. García Aparicio, A.M., Rey, J.R., Sanz, A.H., Alvarez, J.S. Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab. Clin Rheumatol 2007, 26, 811-813.
122. Mancini, S., Amorotti, E., Vecchio, S., Ponz deLeon, M., Roncucci, L. Infliximab-related hepatitis: Discussion of a case and review of the literature. Intern Emerg Med 2010, 5, 193-200.
123. Massarotti, M., Marasini, B. Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumabrelated hepatotoxicity. Int J Immunopathol Pharmacol 2009, 22, 547-549.
124. Leak, A.M., Rincon-Aznar, B. Hepatotoxicity associated with etanercept in psoriatic arthritis. J Rheumatol 2008, 35, 2286-2287.
125. Balato, N., Gallo, L., Gaudiello, F., Chiurazzi, F., Ayala, F. Transient and reversible thrombocytopenia in a psoriatic patient treated with etanercept. J Dermatolog Treat 2010, 21, 117-118.
126. Kuruvilla, J., Leitch, H.A., Vickars, L.M., Galbraith, P.F., Li, C.H., Al-Saab, S., Naiman, S.C. Aplastic anemia following administration of a tumor necrosis factor- a inhibitor. Eur J Haematol 2003, 71, 396-398.
127. Vidal, F., Fontova, R., Richart, C. Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med 2003, 139, W-W63.
128. Brunasso, A.M., Massone, C. Thrombocytopenia associated with the use of anti-tumor necrosis factor- A agents for psoriasis. J Am Acad Dermatol 2009, 60, 781-785.
129. Osting, V.C., Carter, J.D. A safety assessment of tumor necrosis factor antagonists during pregnancy. Expert Opin Drug Saf 2010, 9, 421-429.
130. Berthelot, J.M., De Bandt, M., Goupille, P., Solau-Gervais, E., Lioté, F., Goeb, V., Azaïs, I., Martin, A., Pallot-Prades, B., Maugars, Y., Mariette, X.; CRI (Club Rhumatismes et Inflammation). Exposition to anti-TNF drugs during pregnancy: Outcome of 15 cases and review of the literature. Joint Bone Spine 2009, 76, 28-34.
131. Puig, L., Barco, D., Alomar, A. Treatment of psoriasis with anti-TNF drugs during pregnancy: Case report and review of the literature. Dermatology (Basel) 2010, 220, 71-76.
132. Moustou, A.E., Matekovits, A., Dessinioti, C., Antoniou, C., Sfikakis, P.P., Stratigos, A.J. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: A clinical review. J Am Acad Dermatol 2009, 61, 486-504.
133. Lecluse, L.L., Dowlatshahi, E.A., Limpens, C.E., de Rie, M.A., Bos, J.D., Spuls, P.I. Etanercept: An overview of dermatologic adverse events. Arch Dermatol 2011, 147, 79-94.
134. Mortel, M.R., Emer, J. Prospective new biologic therapies for psoriasis and psoriatic arthritis. J Drugs Dermatol 2010, 9, 947-958.
135. Rozenblit, M., Lebwohl, M. New biologics for psoriasis and psoriatic arthritis. Dermatol Ther 2009, 22, 56-60.
136. Kavanaugh A., McInnes I., Mease P.J., editors. Golimumab, a new human TNF- a antibody administered as a monthly subcutaneous injection in psoriatic arthritis: 24 week efficacy and safety results of the randomized, placebo controlled GO-REVEAL study. European League Against Rheumatism; 2008 June 11-14; Paris.
137. Girolomoni, G., Gisondi, P. Psoriasis and systemic inflammation: Underdiagnosed enthesopathy. J Eur Acad Dermatol Venereol 2009, 23 Suppl 1, 3-8.
138. Ardizzone, S., Bianchi Porro, G. Inflammatory bowel disease: New insights into pathogenesis and treatment. J Intern Med 2002, 252, 475-496.
139. Asakura, H., Suzuki, K., Honma, T. Recent advances in basic and clinical aspects of inflammatory bowel disease: Which steps in the mucosal inflammation should we block for the treatment of inflammatory bowel disease? World J Gastroenterol 2007, 13, 2145-2149.
140. Kaser, A., Zeissig, S., Blumberg, R.S. Inflammatory bowel disease. Annu Rev Immunol 2010, 28, 573-621.
141. Bruewer, M., Luegering, A., Kucharzik, T., Parkos, C.A., Madara, J.L., Hopkins, A.M., Nusrat, A. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 2003, 171, 6164-6172.
142. Zhang, S.Z., Zhao, X.H., Zhang, D.C. Cellular and molecular immunopathogenesis of ulcerative colitis. Cell Mol Immunol 2006, 3, 35-40.
143. Rachmilewitz, D., Stamler, J.S., Bachwich, D., Karmeli, F., Ackerman, Z., Podolsky, D.K. Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Gut 1995, 36, 718-723.
144. Kolios, G., Valatas, V., Ward, S.G. Nitric oxide in inflammatory bowel disease: A universal messenger in an unsolved puzzle. Immunology 2004, 113, 427-437.
145. Rafa, H., Amri, M., Saoula, H., Belkhelfa, M., Medjeber, O., Boutaleb, A., Aftis, S., Nakmouche, M., Touil-Boukoffa, C. Involvement of interferon-? in bowel disease pathogenesis by nitric oxide pathway: A study in Algerian patients. J Interferon Cytokine Res 2010, 30, 691-697.
146. Jurjus, A.R., Khoury, N.N., Reimund, J.M. Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods 2004, 50, 81-92.
147. Wirtz, S., Neurath, M.F. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev 2007, 59, 1073-1083.
148. Okayasu, I., Hatakeyama, S., Yamada, M., Ohkusa, T., Inagaki, Y., Nakaya, R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990, 98, 694-702.
149. Cooper, H.S., Murthy, S.N., Shah, R.S., Sedergran, D.J. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993, 69, 238-249.
150. Murthy, S.N., Cooper, H.S., Shim, H., Shah, R.S., Ibrahim, S.A., Sedergran, D.J. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci 1993, 38, 1722-1734.
151. Rioux, K.P., Fedorak, R.N. Probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol 2006, 40, 260-263.
152. Balfour Sartor R. Microbial influences in inflammatory bowel diseases. Gastroenterol 2008, 134, 577-594.
153. Damaskos, D., Kolios, G. Probiotics and prebiotics in inflammatory bowel disease: Microflora 'on the scope'. Br J Clin Pharmacol 2008, 65, 453-467.
154. Bengmark, S. Pre-, pro- and synbiotics. Curr Opin Clin Nutr Metab Care 2001, 4, 571-579.
155. Stall, A.M., Fariñas, M.C., Tarlinton, D.M., Lalor, P.A., Herzenberg, L.A., Strober, S., Herzenberg, L.A. Ly-1 B-cell clones similar to human chronic lymphocytic leukemias routinely develop in older normal mice and young autoimmune (New Zealand Black-related) animals. Proc Natl Acad Sci USA 1988, 85, 7312-7316.
156. Elson, C.O., Sartor, R.B., Tennyson, G.S., Riddell, R.H. Experimental models of inflammatory bowel disease. Gastroenterology 1995, 109, 1344-1367.
157. Arai, Y., Takanashi, H., Kitagawa, H., Okayasu, I. Involvement of interleukin-1 in the development of ulcerative colitis induced by dextran sulfate sodium in mice. Cytokine 1998, 10, 890-896.
158. Southey, A., Tanaka, S., Murakami, T., Miyoshi, H., Ishizuka, T., Sugiura, M., Kawashima, K., Sugita, T. Pathophysiological role of nitric oxide in rat experimental colitis. Int J Immunopharmacol 1997, 19, 669-676.
159. Dijkstra, G., Moshage, H., van Dullemen, H.M., de Jager-Krikken, A., Tiebosch, A.T., Kleibeuker, J.H., Jansen, P.L., van Goor, H. Expression of nitric oxide synthases and formation of nitrotyrosine and reactive oxygen species in inflammatory bowel disease. J Pathol 1998, 186, 416-421.
160. Morris, S.M., Jr, Billiar, T.R. New insights into the regulation of inducible nitric oxide synthesis. Am J Physiol 1994, 266, E829-E839.
161. Drapier, J.C. [Nitric oxide and macrophages]. Pathol Biol 1997, 45, 110-114.
162. Touil-Boukoffa, C., Bauvois, B., Sancéau, J., Hamrioui, B., Wietzerbin, J. Production of nitric oxide (NO) in human hydatidosis: Relationship between nitrite production and interferon-gamma levels. Biochimie 1998, 80, 739-744.
163. Dieleman, L.A., Ridwan, B.U., Tennyson, G.S., Beagley, K.W., Bucy, R.P., Elson, C.O. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 1994, 107, 1643-1652.
164. Singer, I.I., Kawka, D.W., Scott, S., Weidner, J.R., Mumford, R.A., Riehl, T.E., Stenson, W.F. Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology 1996, 111, 871-885.
165. Neish, A.S., Gewirtz, A.T., Zeng, H., Young, A.N., Hobert, M.E., Karmali, V., Rao, A.S., Madara, J.L. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science 2000, 289, 1560-1563.
166. Petrof, E.O., Kojima, K., Ropeleski, M.J., Musch, M.W., Tao, Y., De Simone, C., Chang, E.B. Probiotics inhibit nuclear factorkappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. Gastroenterology 2004, 127, 1474-1487.
167. McCarthy, J., O'Mahony, L., O'Callaghan, L., Sheil, B., Vaughan, E.E., Fitzsimons, N., Fitzgibbon, J., O'Sullivan, G.C., Kiely, B., Collins, J.K., Shanahan, F. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003, 52, 975-980.
168. Peña, J.A., Rogers, A.B., Ge, Z., Ng, V., Li, S.Y., Fox, J.G., Versalovic, J. Probiotic Lactobacillus spp. diminish Helicobacter hepaticusinduced inflammatory bowel disease in interleukin-10-deficient mice. Infect Immun 2005, 73, 912-920.
169. Rigby, R.J., Knight, S.C., Kamm, M.A., Stagg, A.J. Production of interleukin (IL)-10 and IL-12 by murine colonic dendritic cells in response to microbial stimuli. Clin Exp Immunol 2005, 139, 245-256.
170. Ulisse, S., Gionchetti, P., D'Alò, S., Russo, F.P., Pesce, I., Ricci, G., Rizzello, F., Helwig, U., Cifone, M.G., Campieri, M., De Simone, C. Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: Effects of probiotic treatment. Am J Gastroenterol 2001, 96, 2691-2699.
171. Rachmilewitz, D., Katakura, K., Karmeli, F., Hayashi, T., Reinus, C., Rudensky, B., Akira, S., Takeda, K., Lee, J., Takabayashi, K., Raz, E. Toll-like receptor 9 signaling mediates the antiinflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004, 126, 520-528.
172. Roberfroid, M.B., Van Loo, J.A., Gibson, G.R. The bifidogenic nature of chicory inulin and its hydrolysis products. J Nutr 1998, 128, 11-19.
173. Wollowski, I., Rechkemmer, G., Pool-Zobel, B.L. Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr 2001, 73, 451S-455S.
174. Satchithanandam, S., Vargofcak-Apker, M., Calvert, R.J., Leeds, A.R., Cassidy, M.M. Alteration of gastrointestinal mucin by fiber feeding in rats. J Nutr 1990, 120, 1179-1184.
175. Frankel, W., Zhang, W., Singh, A., Bain, A., Satchithanandam, S., Klurfeld, D., Rombeau, J. Fiber: Effect on bacterial translocation and intestinal mucin content. World J Surg 1995, 19, 144-8; discussion 148.
176. Videla S, Vilaseca J, Garcia-Lafuente A, Antolin M, Crespo E, Guarner F, Malagelada JR. Dietary inulin prevents distal colitis induced by dextran sulfate sodium (DSS). Gastroenterol 1998, 114, A1110.
177. Kolida, S., Tuohy, K., Gibson, G.R. Prebiotic effects of inulin and oligofructose. Br J Nutr 2002, 87 Suppl 2, S193-S197.